HatemHSolimanMD

Breast Cancer

Associate Member Breast and Immunology Departments Medical Director, Clinical Trials Office H. Lee Moffitt Cancer Center and Research Institute Associate Professor Department of Oncologic Sciences University of South Florida

Request Appointment

Overview of Dr. Soliman

Dr. Hatem Soliman is an oncologist in Tampa, FL and is affiliated with multiple hospitals in the area, including H. Lee Moffitt Cancer Center and Research Institute and Tampa General Hospital. He received his medical degree from Medical College of Georgia and has been in practice 15 years. Dr. Soliman accepts several types of health insurance, listed below. He is one of 72 doctors at Tampa General Hospital and one of 173 doctors at H. Lee Moffitt Cancer Center and Research Institute who specialize in Oncology. He has more than 100 publications and over 500 citings.

Office
12902 USF Magnolia Dr
Mccgme
Tampa, FL 33612
Book by Phone+1(563) 362-9188

Education & Training

University of South Florida MorsaniFellowship, Hematology and Medical Oncology, 2005 - 2008
University of South Florida MorsaniResidency, Internal Medicine, 2002 - 2005
Medical College of Georgia at Augusta UniversityClass of 2002
University of Georgia AthensBS, 1996

Certifications & Licensure

FL State Medical License 2004 - 2025
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

Nominated for Physician of the Year Moffitt Cancer Center, 2013
Resident of the Month Award Medical College of Georgia, 2002
Kappa Beta Phi Honor Society Member University of Georgia, 1996
Phi Beta Kappa Honor Society 1995
Join now to see all

Clinical Trials

Vaccine Therapy and 1-MT in Treating Patients With Metastatic Breast Cancer Start of enrollment: 2009 Dec 28
Completed
Phase 1, Phase 2
1-Methyl-D-Tryptophan and Docetaxel in Treating Patients With Metastatic Solid Tumors Start of enrollment: 2010 Sep 01
Completed
Phase 1
C11 AMT Positron Emission Tomography (PET) Imaging in Patients With Metastatic Invasive Breast Cancer Start of enrollment: 2013 Jan 01
Withdrawn
Not Applicable
Efficacy and Safety Study of NeuVax™ (Nelipepimut-S or E75) Vaccine to Prevent Breast Cancer Recurrence Start of enrollment: 2011 Nov 01
Completed
Phase 3
Trial Evaluating Dovitinib Combined With Fulvestrant, in Postmenopausal Patients With HER2- and HR+ Breast Cancer Start of enrollment: 2012 Apr 01
Terminated
Phase 2
Combination Immunotherapy With Herceptin and the HER2 Vaccine NeuVax Start of enrollment: 2013 May 21
Completed
Phase 2
PRospective Study Of MammaPrint in Patients With an Intermediate Recurrence Score Start of enrollment: 2012 May 01
Completed
Characterization of Circulating Tumor Cells (CTC) From Patients With Metastatic Breast Cancer Using the CTC-Endocrine Therapy Index Start of enrollment: 2013 Apr 01
Completed
Study of Chemotherapy in Combination With IDO Inhibitor in Metastatic Breast Cancer Start of enrollment: 2013 Feb 01
Completed
Phase 2
A Phase I Dose Escalation Study of Eribulin Plus Weekly Carboplatin for Metastatic Breast Patients Start of enrollment: 2013 Feb 06
Completed
Phase 1
COGNUTRIN in Breast Cancer Survivors Start of enrollment: 2014 Jul 30
Completed
Early Phase 1
Yoga for Aromatase Inhibitor-associated Joint Pain Start of enrollment: 2013 Sep 01
Completed
Not Applicable
A Study of Abemaciclib (LY2835219) Combined With Fulvestrant in Women With Hormone Receptor Positive HER2 Negative Breast Cancer Start of enrollment: 2014 Jul 22
Active, not recruiting
Phase 3
Phase I/IIa Trial of Gemcitabine Plus Trastuzumab and Pertuzumab in Previously Treated Metastatic HER2+ Breast Cancer Start of enrollment: 2014 Sep 05
Completed
Phase 1, Phase 2
Fractionated Stereotactic Radiotherapy (FSRT) in Treatment of Brain Metastases Start of enrollment: 2014 Oct 09
Terminated
Phase 1
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer Start of enrollment: 2016 Feb 23
Completed
Phase 1
Talimogene Laherparepvec in Combination With Neoadjuvant Chemotherapy in Triple Negative Breast Cancer Start of enrollment: 2017 May 02
Active, not recruiting
Phase 1, Phase 2
Adjuvant PVX-410 Vaccine and Durvalumab in Stage II/III Triple Negative Breast Cancer Start of enrollment: 2016 Aug 01
Active, not recruiting
Phase 1
Phase I-II Study of Interferon-gamma in Patients With HER-2 Positive Breast Cancer Start of enrollment: 2017 Jun 23
Completed
Phase 1, Phase 2
PET-CT Imaging Using FDG-labeled Human Erythrocytes in Breast Cancer Patient Start of enrollment: 2020 Dec 01
Withdrawn
Early Phase 1
HER2 Directed Dendritic Cell Vaccine During Neoadjuvant Therapy of HER2+Breast Cancer Start of enrollment: 2018 Jun 06
Active, not recruiting
Early Phase 1
Radiation Therapy Followed by Intrathecal Trastuzumab/Pertuzumab in HER2+ Breast Leptomeningeal Disease Start of enrollment: 2020 Dec 10
Recruiting
Phase 1, Phase 2
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases Start of enrollment: 2021 Nov 30
Recruiting
Phase 1, Phase 2
Study of Screening Brain MRIs in Stage IV Breast Cancer Start of enrollment: 2021 Dec 21
Recruiting
Roles: Sub-Investigator
Join now to see all

Publications & Presentations

PubMed

Alteration of the Tumor Microenvironment With Intratumoral Dendritic Cells Before Chemotherapy in ERBB2 Breast Cancer: A Nonrandomized Clinical Trial.
Hyo S Han, Amy L Aldrich, Saurabh K Garg, R Jared Weinfurtner, Jonathan V Nguyen
JAMA Oncology. 2024-12-05
Multi-institutional report of trastuzumab deruxtecan and stereotactic radiosurgery for HER2 positive and HER2-low breast cancer brain metastases.
Vaseem M Khatri, Mariella A Mestres-Villanueva, Sreenija Yarlagadda, Ajay Doniparthi, David B Smith
NPJ Breast Cancer. 2024-11-21
Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
Saya Jacob, Anika Christofferson, Samantha Fisch, Peter Norwood, Paolo Castillo
Breast Cancer Research and Treatment. 2024-09-21

Journal Articles

Analysis of indoleamine 2-3 dioxygenase (IDO1) expression in breast cancer tissue by immunohistochemistry
Soliman H, Rawal B, Fulp J, Lee JH, Lopez A, Bui MM, Khalil F, Antonia S, Yfantis HG, Lee DH, Dorsey TH, Ambs S, Cancer Immunol Immunother., 1/1/2013
Indoleamine 2,3-dioxygenase: is it an immune suppressor?
Soliman H, Mediavilla-Varela M, Antonia S., Cancer J., 1/1/2010
A GM-CSF and CD40L bystander vaccine is effective in a murine breast cancer model
Soliman H, Mediavilla-Varela M, Antonia SJ, Breast Cancer (Dove Med Press)., 1/15/2015
Nucleolar repression facilitates initiation and maintenance of senescence
Yang L, Song T, Chen L, Soliman H, Chen J., Cell Cycle., 1/17/2015
Join now to see all

Abstracts/Posters

A phase 1/2 study of Ad.p53 DC vaccine with indoximod immunotherapy in metastatic breast cancer.
Soliman H, Minton S, Ismail-Khan R, Han H, Vahanian N, Link C, Kennedy G, Streicher H, Sullivan D, Antonia S, San Antonio Breast Cancer Symposium, San Antonio, TX, 1/1/2014
A phase 1 study of ad.p53 DC vaccine in combination with indoximod in metastatic solid tumors.
Soliman H, Minton S, Han H, Ismail-Khan R, Mahipal A, Janssen W, Streicher H, Vahanian N, Link C, Ramsey W, Antonia S, Sullivan D, J Clin Oncol, ASCO Annual Meeting, Chicago, IL, 1/1/2013
Combination immunotherapy with PD-L1 blockade and Poly I:C in a murine breast cancer model.
Hatem Soliman, Ashley R. Nelson., Proceedings of the 105th Annual Meeting of the American Association for Cancer Research, AACR, Cancer Res, San Diego, CA, 2014; Philadelphia, PA, 2014, 1/5./2014

Lectures

In silico evaluation of the 12-gene molecular score (EndoPredict) and the recurrence score (Oncotype DX) as predictors of response to neo-adjuvant chemotherapy in estr...
2018 ASCO Annual Meeting - Chicago, Illinois - 06/2/2018

Press Mentions

Oncolytic Virus Therapy Shows Promising Results in Early-Stage TNBCFebruary 23rd, 2023
Triple-Negative Breast Cancer: Could a Cancer-Killing Virus Clear up Tumors?February 19th, 2023
Oncolytic Virus Therapy Yields PromisingFebruary 10th, 2023
Join now to see all

Professional Memberships

American Society of Clinical Oncology - ASCO
Member

Insurance Accepted

Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
First Health PPO
Great West PPO
HIP of New York - Select PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO
Please verify your coverage with the provider's office directly when scheduling an appointment